{Reference Type}: Journal Article
{Title}: Dolutegravir Resistance in African Programmatic Settings Among Patients With Failure of Dolutegravir-based ART.
{Author}: Murphy RA;Bedesi PH;Perumal N;Gosnell BI;Hatlen TJ;Brijkumar J;
{Journal}: Open Forum Infect Dis
{Volume}: 11
{Issue}: 7
{Year}: 2024 Jul
{Factor}: 4.423
{DOI}: 10.1093/ofid/ofae321
{Abstract}: Dolutegravir resistance is emerging in routine clinical contexts in southern Africa, primarily in patients with prior treatment experience failing dolutegravir-based antiretroviral therapy (ART). This potential issue was raised by The Nucleosides and Darunavir/Dolutegravir in Africa trial that compared dolutegravir and boosted protease inhibitor-based therapy as second-line ART, in which new dolutegravir resistance was observed at failure. However, recent data suggest that also at risk are patients who were transitioned to dolutegravir from non-nucleoside reverse transcriptase inhibitor-based ART while viremic. Identifying patients experiencing failure of dolutegravir with resistance will be difficult given current gaps in viral load monitoring and limited capacity for genotypic resistance testing. As a result, in the short term, most patients affected will go unrecognized, with particularly important implications for patients affected who have advanced HIV or who are pregnant/breastfeeding. Prospective research is needed to understand the scope of the problem, identify additional risk factors, and determine best management. In the short term, for most patients with dolutegravir resistance and prior non-nucleoside reverse transcriptase inhibitor exposure, the best option will be a timely switch to a regimen anchored by a boosted protease inhibitor, with a high genetic barrier to resistance.